Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (53): 9881-9884.doi: 10.3969/j.issn.1673-8225.2011.53.001

    Next Articles

Effects of tacrolimus and sirolimus on generation of Foxp3+ regulatory T cells and recurrence of hepatocellular carcinoma in patients with hepatocellular carcinoma after liver transplantation

Chen Guo-yong, Sun Jian-jun, Li Cai-li, Chen Jian-bin, Tang Gao-feng, Xie Zhan-tao, Zhao Hui-bo, Ji Jie, Jiang Jin-fa   

  1. People’s Hospital of Zhengzhou, Zhengzhou  450003, Henan Province, China
  • Received:2011-09-13 Revised:2011-11-25 Online:2011-12-31 Published:2011-12-31
  • Contact: Sun Jian-jun, Master, Associate chief physician, People’s Hospital of Zhengzhou, Zhengzhou 450003, Henan Province, China sunjjandy@sohu.com
  • About author:Chen Guo-yong, Associate chief physician, People’s Hospital of Zhengzhou, Zhengzhou 450003, Henan Province, China andydapao@163.com
  • Supported by:

    Science and Technology Program of Henan Province, No. 092102310347*

PDF

616

Abstract:

BACKGROUND: Increasing the generation and function of regulatory T cells has become an effective means of maintaining the immune tolerance of grafts.
OBJECTIVE: To study the effects of tacrolimus and sirolimus on generation of Foxp3+ regulatory T cells and recurrence in patients with hepatocellular carcinoma after liver transplantation.
METHODS: Forty patients with hepatocellular carcinoma accord to Milan criteria were randomly divided into tacrolimus group and sirolimus group with 20 patients in each group. Peripheral blood of patients was extracted monthly during the 2-12 months after transplantation for detection of Foxp3+ regulatory T cells. Color doppler ultrasound and the peripheral blood alpha-fetoprotein detection were performed. Liver biopsy was performed to observe the rejection and recurrence. 
RESULTS AND CONCLUSION: Flow cytometry results showed that positive rate of Foxp3+ regulatory T cells in the sirolimus group was significantly increased compared with the tacrolimus group (P < 0.05). Liver biopsy showed no significant difference in rejection between the two groups (P > 0.05). The hepatocellular carcinoma recurrence rate in the sirolimus group was obviously lower than the tacrolimus group by color doppler ultrasound, peripheral blood alpha-fetoprotein detection and liver biopsy (operation) (P < 0.05). It is suggested that sirolimus is superior to tacrolimus in inhibiting recurrence of liver transplantation, and the rejection of sirolimus does not increase compared with tacrolimus, or even has better results in immunological tolerance.

CLC Number: